HPV vaccines – A review of the first decade

Gynecologic Oncology

Volumn 146, Issue 1, 2017, Pages 196-204

  Harper, Diane M ^a   DeMars, Leslie R ^b  

^a University of Louisville School of Medicine   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Cervarix; Cervical cancer incidence; CIN 3; Efficacy; Gardasil; Gardasil9; HPV vaccine immunogenicity; Persistent HPV infection

Indexed keywords

WART VIRUS VACCINE;

CANCER IMMUNIZATION; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOGENICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ADOLESCENT; ALPHAPAPILLOMAVIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHILD; IMMUNOLOGY; PAPILLOMAVIRUS INFECTIONS; PREVENTIVE HEALTH SERVICE; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

ADOLESCENT; ALPHAPAPILLOMAVIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHILD; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 85018630320     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2017.04.004     Document Type: Review

References (69)

1. How many cancers are linked with HPV each year? [Internet] Available from www.cdc.gov/cancer/hpv/statistics/cases.htm.
2. Bray, F., Ferlay, J., Laversanne, M., Vrewster, D.H., Gombe Mbalawa, C., Kohler, et al. Cancer incidence in five continents: inclusion criteria highlights from volume X and the global status of cancer registration. Int. J. Cancer 137 (2015), 2060–2071.
3. Fernandez, L.M., Pendleton, M.E., Wright, R.B., Harper, D.M., Chapter 29 bivalent HPV vaccine approved for cervical cancer prevention in females. Ayhan, A., Reed, N., Gultekin, M., Dursun, P., (eds.) Textbook of Gynaecological Oncology, third ed., 2016, Gunes Publishing, Ankara, 247–278.
4. LaJoie, A.S., Fernandez, L.M., Pendleton, M.E., Harper, D.M., Chapter 30 quadrivalent and nonavalent HPV vaccine approved for males and females for HPV associated diseases. Ayhan, A., Reed, N., Gultekin, M., Dursun, P., (eds.) Textbook of Gynaecological Oncology, third ed., 2016, Gunes Publishing, Ankara, 279–308.
5. Gardasil9 package insert [Internet] Available from http://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm426457.pdf.
6. Cervarix Package Insert. 2009, GlaxoSmithKline Biologicals, Rixensart, Belgium http://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm186981.pdf.
7. Giannini, S.L., Hanon, E., Moris, P., Van Mechelen, M., Morel, S., Dessy, F., et al. Enhanced humoral and memory B cellular immunity using HPV 1/618 L1 VLP vaccine formulated with the MPL/aluminum salt combination (AS04) compared to aluminium salt only. Vaccine 24 (2006), 5937–5949.
8. IARC HPV Working Group Report, Primary End-points for Prophylactic HPV Vaccine Trials. vol. 7, 2013 (Lyon, France. ISBN 978-92-832-2451-8).
9. Olsson, S.E., Kjaer, S.K., Sigurdsson, K., Iversen, O.E., Hernandez-Avila, M., Wheeler, C.M., et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum. Vaccin. 5:10 (2009), 696–704.
10. Einstein, M.H., Takacs, P., Chatterjee, A., Sperling, R.S., Chakhtoura, N., Blatter, M.M., et al. Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18–45 years: end-of-study analysis of a phase III randomized trial. Hum. Vaccin. Immunother. 10:12 (2014), 3435–3445.
11. Einstein, M.H., Levin, M.J., Chatterjee, A., Chakhtoura, N., Takacs, P., Catteau, G., et al. Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18–45 years: follow-up through month 48 in a phase III randomized study. Hum. Vaccin. Immunother. 10:12 (2014), 3455–3465, 10.4161/hv.36117.
12. Einstein, M.H., Baron, M., Levin, M.J., Chatterjee, A., Fox, B., Scholar, S., et al. Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18–45 years. Hum. Vaccin. 7:12 (2011), 1359–1373.
13. Einstein, M.H., Baron, M., Levin, M.J., Chatterjee, A., Fox, B., Scholar, S., et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12–24 in a Phase III randomized study of healthy women aged 18–45 years. Hum. Vaccin. 7:12 (2011), 1343–1358, 10.4161/hv.7.12.18281 (Epub 2011 Dec 1).
14. Godi, A., Bissett, S.L., Miller, E., Beddows, S., Relationship between humoral immune responses against HPV16, HPV18, HPV31 and HPV45 in 12–15 year old girls receiving Cervarix® or Gardasil® vaccine. PLoS One, 10(10), 2015 Oct 23, e0140926, 10.1371/journal.pone.0140926.
15. Naud, P.S., Roteli-Martins, C.M., De Carvalho, N.S., Teixeira, J.C., de Borba, P.C., Sanchez, N., et al. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum. Vaccin. Immunother. 10:8 (2014), 2147–2162, 10.4161/hv.29532.
16. Nygard, M., Saah, A., Munk, C., Tryggvadottir, L., Enerly, E., Hortlund, M., et al. Evaluation of the long-term anti-human papillomavirus 6 (HPV6), 11, 16, and 18 immune responses generated by the quadrivalent HPV vaccine. Clin. Vaccine Immunol. 22:8 (2015), 943–948.
17. Statistical Review of Gardasil9-[Internet] http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM428669.pdf.
18. Olsson, S.E., Villa, L.L., Costa, R.L., Petta, C.A., Andrade, R.P., Malm, C., et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 25:26 (Jun 21, 2007), 4931–4939.
19. Gilca, V., Sauvageau, C., Boulianne, N., De Serres, G., Crajden, M., Ouakki, M., et al. The effect of a booster dose of quadrivalent or bivalent HPV vaccine when administered to girls previously vaccinated with two doses of quadrivalent HPV vaccine. Hum. Vaccin. Immunother. 11:3 (2015), 732–738.
20. Garland, S.M., Cheung, T.H., McNeill, S., Petersen, L.K., Romaguera, J., Vazquez-Narvaez, J., et al. Safety and immunogenicity of a 9-valent HPV vaccine in females 12–26 years of age who previously received the quadrivalent HPV vaccine. Vaccine 33:48 (2015), 6855–6864.
21. Chesson, H.W., Laprise, J.F., Brisson, M., Markowitz, L.E., Impact and cost-effectiveness of 3 doses of 9-valent human papillomavirus (HPV) vaccine among US females previously vaccinated with 4-valent HPV vaccine. J. Infect. Dis. 213:11 (2016), 1694–1700.
22. Barnabas, R.V., Laukkanen, P., Koskela, P., Kontula, O., Lehtinen, M., Garnett, G.P., Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modeling analyses. PLoS Med., 3, 2006, e138.
23. World Health Organization website Immunization Vaccines and Biologicals-Human Papillomavirus [Internet]. http://www.who.int/immunization/diseases/hpv/en/.
24. Meites, E., Kempe, A., Markowitz, L.E., Use of a 2-dose schedule for human papillomavirus vaccination — updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb. Mortal. Wkly Rep. 65 (2016), 1405–1408, 10.15585/mmwr.mm6549a5.
25. Safaeian, M., Porras, C., Pan, Y., Kreimer, A., Schiller, J.T., Gonzalez, P., et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev. Res. (Phila.) 6:11 (2013), 1242–1250, 10.1158/1940-6207.CAPR-13-0203.
26. Sankaranarayanan, R., Prabhu, P.R., Pawlita, M., Gheit, T., Bhatla, N., Muwonge, R., et al. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study. Lancet Oncol. 17:1 (2016 Jan), 67–77, 10.1016/S1470-2045(15)00414-3 (Epub 2015 Dec 2).
27. Donken, R., Knol, M.J., Bogaards, J.A., van der Klis, F.R.M., CJLM, Meijer, de Melker, H.E., Inconclusive evidence for non-inferior immunogenicity of two compared with three dose HPV immunization schedules in preadolescent girls: a meta-analysis. J. Infect. 71 (2015), 61–73.
28. Neuzil, K.M., Canh, D.G., Thiem, V.D., Janmohamed, A., Huong, V.M., Tang, Y., et al. Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized non-inferiority trial. JAMA 305:14 (2011), 1424–1431.
29. LaMontagne, D.S., Thiem, V.D., Huong, V.M., Tang, Y., Neuzil, K.M., Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose. J. Infect. Dis. 208:8 (Oct 15, 2013), 1325–1334.
30. Leung, T.F., Liu, A.P., Lim, F.S., Thollot, F., Oh, H.M., Lee, B.W., et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9–14 years: results to month 12 from a randomized trial. Hum. Vaccin. Immunother. 11:7 (2015), 1689–1702, 10.1080/21645515.2015.1050570.
31. Iversen, O.E., Miranda, M.J., Ullied, A., Soerdal, T., Lazarus, E., Chokephaibulkit, K., Block, S.L., et al. Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women. JAMA 316:22 (2016), 2411–2421.
32. Castellsagué, X., Muñoz, N., Pitisuttithum, P., Ferris, D., Monsonego, J., Ault, K., et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age. Br. J. Cancer 105:1 (2011 Jun 28), 28–37, 10.1038/bjc.2011.185 (Epub 2011 May 31).
33. Schwarz, T., Spaczynski, M., Kaufmann, A., Wysocki, J., Gałaj, A., Schulze, K., et al. Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15–55 years and first-time modelling of antibody responses in mature women: results from an open-label 6-year follow-up study. BJOG 122:1 (2015), 107–118.
34. Skinner, S.R., Szarewski, A., Romanowski, B., Garland, S.M., Lazcano-Ponce, E., Salmerón, J., et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet 384:9961 (Dec 20, 2014), 2213–2227, 10.1016/S0140-6736(14)60920-X (Epub 2014 Sep 1).
35. Schwarz, T.F., Galaj, A., Spaczynski, M., Wysocki, J., Kaufmann, A.M., Suryakiran, P.V., et al. Persistence of Immune Response 10 years After Administration of the Human Papillomavirus (HPV) 16/18 AS04-adjuvanted Vaccine to Women Aged 15–55 Years. 2016, European Research Organization on Genital Infection and Neoplasia (EUROGIN) Internet http://eurogin.com/2016/images/doc/eurogin-2016-1bstracts-part-2.pdf.
36. Villa, L.L., Costa, R.L.R., Petta, C.A., Andrade, R.P., Paavonen, J., Iversen, O.E., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br. J. Cancer, 95(11), 2006.
37. Statistical Review of Gardasil9 [Internet] http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM429166.pdf.
38. FUTURE I/II Study Group, Dillner, J., Kjaer, S.K., Wheeler, C.M., Sigurdsson, K., Iversen, O.E., et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ, 341, 2010, c3493 Clinical research ed.
39. Medical Officer Review of Gardasil by FDA in 2008 [Internet] http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM111274.pdf.
40. Joura, E.A., Giuliano, A.R., Iversen, O.E., Bouchard, C., Mao, C., Mehlsen, J., et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N. Engl. J. Med. 372:8 (2015), 711–723.
41. Munoz, N., Kjaer, S.K., Sigurdsson, K., Iversen, O.E., Hernandez-Avila, M., et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV associated genital diseases in young women. J. Natl. Cancer Inst. 102:5 (2010), 325–339.
42. Giuliano, A., Joura, E.A., Iversen, O.E., Efficacy of a novel 9-valent HPV L1 vaccine against disease irrespective of HPV type. 29th International Papillomavirus Conference and Public Health & Clinical Workshops, 2014 August 24, 2014. (Seattle, Washington).
43. Castellsague, X., Munoz, N., Pitisuttithum, P., Ferris, D., Monsonego, J., Ault, K., et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age. Br. J. Cancer 105:1 (2011), 28–37.
44. National, State and local Area Vaccination Coverage Among Adolescents Aged 13–17 years – United States. 2009 [Internet] available from http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5932a3.htm?s_cid mm5932a3_w.
45. Paavonen, J., Naud, P., Salmerón, J., Wheeler, C.M., Chow, S.N., Apter, D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374:9686 (2009), 301–314.
46. Lehtinen, M., Paavonen, J., Wheeler, C.M., Jaisamrarn, U., Garland, S.M., Castellsagué, X., et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 13:1 (2012), 89–99.
47. Apter, D., Wheeler, C.M., Paavonen, J., Castellsagué, X., Garland, S.M., Skinner, S.R., et al. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial. Clin. Vaccine Immunol. 22:4 (2015), 361–373.
48. Harari, A., Chen, Z., Rodríguez, A.C., Hildesheim, A., Porras, C., Herrero, R., et al. Cross-protection of the bivalent human papillomavirus (HPV) vaccine against variants of genetically related high-risk HPV infections. J. Infect. Dis. 213:6 (2016), 939–947, 10.1093/infdis/jiv519 (Epub 2015 Oct 30).
49. Wheeler, C.M., Castellsagué, X., Garland, S.M., Szarewski, A., Paavonen, J., Naud, P., et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 13:1 (2012), 100–110, 10.1016/S1470-2045(11)70287-X (Epub 2011 Nov 8).
50. Wheeler, C.M., Skinner, S.R., Lazcano Ponce, E., del Rosario-Raymundo, M.R., McNeil, S. et al., Human papillomavirus (HPV)-16/18 AS04 adjuvanted vaccine efficacy in > 26 year old women: end of study (year 7) results from VIVIANE, a randomized multinational trial. 30th International Papillomavirus Conference, 2011, Abstract HPV15-0279, Lisbon, Portugal.
51. Majewski, S., Bosch, F.X., Dillner, J., Iversen, O.E., Kjaer, S.K., Muñoz, N., et al. The impact of a quadrivalent human papillomavirus (types 6, 11, 16, 18) virus-like particle vaccine in European women aged 16 to 24. J. Eur. Acad. Dermatol. Venereol. 23:10 (Oct 2009), 1147–1155, 10.1111/j.1468-3083.2009.03266.x (Epub 2009 Apr 23).
52. Villa, L.L., Ault, K.A., Giuliano, A.R., Costa, R.L., Petta, C.A., Andrade, R.P., et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine 24:27–28 (Jul 7, 2006), 5571–5583 (Epub 2006 May 15).
53. Bhatla, N., Suri, V., Basu, P., Shastri, S., Datta, S.K., Bi, D., et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women. J. Obstet. Gynaecol. Res. 36:1 (2010 Feb), 123–132, 10.1111/j.1447-0756.2009.01167.x.
54. Bosch, F.X., Robles, C., Díaz, M., Arbyn, M., Baussano, I., Clavel, C., et al. HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nat. Rev. Clin. Oncol. 13:2 (Feb 2016), 119–132, 10.1038/nrclinonc.2015.146 (Epub 2015 Sep 1).
55. Herrero, R., Quint, W., Hildesheim, A., Gonzalez, P., Struijk, L., Katki, H.A., et al. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS One, 8(7), Jul 17, 2013, e68329, 10.1371/journal.pone.0068329.
56. Lang Kuhs, K.A., Gonzalez, P., Rodriguez, A.C., van Doorn, L.J., Schiffman, M., Struijk, L., et al. Reduced prevalence of vulvar HPV16/18 infection among women who received the HPV16/18 bivalent vaccine: a nested analysis within the Costa Rica Vaccine Trial. J. Infect. Dis. 210:12 (Dec 15, 2014), 1890–1899, 10.1093/infdis/jiu357 (Epub 2014 Jun 23).
57. Kreimer, A.R., González, P., Katki, H.A., Porras, C., Schiffman, M., Rodriguez, A.C., et al. Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol. 12:9 (Sep 2011), 862–870, 10.1016/S1470-2045(11)70213-3 (Epub 2011 Aug 22).
58. Beachler, D.C., Kreimer, A.R., Schiffman, M., Herrero, R., Wacholder, S., Rodriguez, A.C., et al. Multisite HPV16/18 vaccine efficacy against cervical, anal, and oral HPV infection. J. Natl. Cancer Inst., 108(1), Oct 14, 2015 pii: djv302 10.1093/jnci/djv302 (Print 2016 Jan).
59. Bruni, L., Diaz, M., Barrionuevo-Rosas, L., Herrero, R., Bray, F., Bosch, F.X., et al. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob. Health 4 (2016), e453–e463, 10.1016/S2214-109X(16)30099-7.
60. Drolet, M., Benard, E., Boily, M.C., Ali, H., Baandrup, L., Bauer, H., et al. Population level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect. Dis. 15:5 (2015), 565–580.
61. Brotherton, J.M., Fridman, M., May, C.L., Chapell, G., Saville, A.M., Gertig, D.M., Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 377:9783 (2011), 2085–2092.
62. Harper, D.M., Nieminen, P., Paavonen, J., Lehtinen, M., Cervical cancer incidence can increase despite HPV vaccination. Lancet Infect. Dis. 10:9 (2010), 594–595.
63. Boone, S.D., Pinkston, C.M., Baumgartner, K.B., Baumgartner, R.N., Harper, S.M., Bonham, A.J., et al. Associations between prior HPV4 vaccine doses and cervical cancer screening participation. Cancer Epidemiol. 42 (Jun 2016), 108–114, 10.1016/j.canep.2016.04.003 (Epub 2016 Apr 18).
64. Paynter, C.A., Van Treeck, B.J., Verdenius, I., Lau, A.W., Dhawan, T., Lash, K.A., et al. Adherence to cervical cancer screening varies by human papillomavirus vaccination status in a high-risk population. Prev. Med. Rep. 2 (Jul 31, 2015), 711–716, 10.1016/j.pmedr.2015.07.011 (eCollection 2015).
65. Hirth, J.M., Lin, Y.L., Kuo, Y.F., Berenson, A.B., Effect of number of human papillomavirus vaccine doses on guideline adherent cervical cytology screening among 19–26 year old females. Prev. Med. 88 (Jul 2016), 134–139, 10.1016/j.ypmed.2016.04.004 (Epub 2016 Apr 13).
66. Budd, A.C., Brotherton, J.M., Gertig, D.M., Chau, T., Drennan, K.T., Saville, M., Cervical screening rates for women vaccinated against human papillomavirus. Med. J. Aust. 201:5 (Sep 1, 2014), 279–282.
67. Palmer, T.J., McFadden, M., Pollock, K.G., Kavanagh, K., Cuschieri, K., Cruickshank, M., et al. HPV immunisation and increased uptake of cervical screening in Scottish women; observational study of routinely collected national data. Br. J. Cancer 114:5 (Mar 1, 2016), 576–581, 10.1038/bjc.2015.473.
68. Beer, H., Hibbitts, S., Brophy, S., Rahman, M.A., Waller, J., Paranjothy, S., Does the HPV vaccination programme have implications for cervical screening programmes in the UK?. Vaccine 32:16 (2014 Apr 1), 1828–1833, 10.1016/j.vaccine.2014.01.087.
69. Herweijer, E., Feldman, A.L., Ploner, A., Arnheim-Dahlström, L., Uhnoo, I., Netterlid, E., et al. The participation of HPV-vaccinated women in a National Cervical Screening Program: population-based cohort study. PLoS One, 10(7), Jul 28, 2015, e0134185, 10.1371/journal.pone.0134185 (eCollection 2015).